Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lumacaftor Mono-Tablets vs Orkambi
NCT05968612Phase 1Completed
- Sponsor
- Qanatpharma
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lumacaftor in heart failure (HF) and subarachnoid hemorrhage (SAH) (3 arms), sponsored by Qanatpharma. Primary endpoints: Maximal Observed Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to 72 Hours and 2 more. Started Nov 2023; status: completed.
02
Drugs
lumacaftor
03
Conditions
heart failure (HF)subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT05968612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968612.